Mosedipimod is under clinical development by Enzychem Lifesciences and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase I drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Mosedipimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mosedipimod (EC-18) is under development for the treatment of acute radiation syndrome, sepsis, rheumatoid arthritis, asthma, nonalcoholic steatohepatitis, liver fibrosis, chronic obstructive pulmonary disease, psoriasis, atopic dermatitis, mustard gas (sulfur mustard) poisoning, chemotherapy induced oral mucositis and coronavirus disease 2019 (Covid-19) pneumonia, coronavirus disease 2019 (Covid-19) associated acute respiratory distress syndrome. It is administered through oral route as capsule. The drug candidate is a monoacetyldiacylglyceride derived from deer antlers. It is developed based on lipid medicine platform technology. The drug candidate was also under development for the treatment of biliary cancer. It was also under development for chemotherapy induced neutropenia (CIN) including febrile and afebrile neutropenia
Enzychem Lifesciences overview
Enzychem Lifesciences (Enzychem) is a Pharmaceutical company. It develops and produces novel drugs and active pharmaceutical ingredients (APIs). It is developing new drugs to treat diseases like asthma, psoriasis, rheumatoid arthritis, atopic dermatitis, acute radiation syndrome, sepsis, and autoimmune disorders. EC-18 is the company’s pipeline product which treats the cancer and inflammationEnzychem servers the patients across the globe. It has research and development center in Chungcheongbuk-do, South Korea. The company has its operations in South korea and the USA. The company is headquartered in Seocho-gu, Seoul, South Korea.
For a complete picture of Mosedipimod’s drug-specific PTSR and LoA scores, buy the report here.